UMIN-CTR Clinical Trial

Basic information
Official scientific title of the study	A study for evaluating the effects of oral intake of food containing lactic acid bacteria on bowel movement of subjects with a tendency for constipation. A randomized, double-blind, placebo-controlled trial.
Title of the study (Brief title)	A study for evaluating the effects of oral intake of food containing lactic acid bacteria on bowel movement of subjects with a tendency for constipation.
Region	Japan

Condition
Condition	Subjects with a tendency for constipation
Classification by specialty	Gastroenterology Adult
Classification by malignancy	Others
Genomic information	NO

Objectives
Narrative objectives1	To evaluate the efficacy of food containing lactic acid bacteria (Lactobacillus brevis) on bowel movement of subjects with a tendency for constipation.
Basic objectives2	Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes	Defecation days, defecation frequency, fecal amount
Key secondary outcomes	Fecal shape, fecal color, fecal odor, feeling after defecation, fecal organic acids, fecal ammonia content, fecal pH, fecal water content, analysis of intestinal microflora

Base
Study type	Interventional

Study design
Basic design	Parallel
Randomization	Randomized
Randomization unit	Individual
Blinding	Double blind -all involved are blinded
Control	Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms	2
Purpose of intervention	Prevention
Type of intervention	Food
Interventions/Control_1	Food containing lactic acid bacteria Duration:2 weeks
Interventions/Control_2	Placebo(not containing lactic acid bacteria) Duration:2 weeks
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit	20 years-old <=
Age-upper limit	65 years-old >
Gender	Male and Female
Key inclusion criteria	(1) Males and females from 20 to 64 years of age (2) Subjects with a tendency for constipation at three to five times of defecation per week (3) Subjects giving written informed consent
Key exclusion criteria	(1) Individuals taking antiflatulents and/or laxatives (including purgative drug) in common use (2) Individuals taking health foods in common use, including food for specified health use, which influence intestinal regulation at the point of screening examination (3) Individuals taking antibiotics and/or drugs which influence laxatives(including purgative drugs) in common use at the point of screening examination (4) Individuals who are not able to stop consumption of foods containing lactic acid bacteria, bifidobacteria, natto bacteria, oligosaccharides, dietary fibers, high amount of sugar alcohol and/or other health foods including food for specified health use, which influence intestinal regulation during the study period (5) Individuals presenting known food allergy (6) Individuals who are suffered from a disease which needs treatment urgently or individuals with severe complications (7) Individuals with a digestive organ disease or surgical history who has an influence on digestive absorption and defecation (8) Individuals who are judged to be unsuitable as a subject from an answer of a subjective background questionnaire (9) Individuals who are pregnant or breast-feeding, or have the will of pregnancy during the study period (10) Individuals who are under treatment or have a history of drug/alcohol dependence (11) Individuals who participate in other clinical studies or who are in willing to participate to these studies using foods, drugs and/or cosmetics (12) Individuals who are judged as unsuitable for the study by the investigator for the other reasons
Target sample size	100

Research contact person
Name of lead principal investigator	Yoshitaka Iwama
Organization	Nihonbashi Cardiology Clinic
Division name	Director
Address	13-4 Nihonbashikodenmacho, Chuo-ku, Tokyo
TEL	03-5641-4133
Email	yiwama@well-sleep.jp

Public contact
Name of contact person	Eiji Yoshikawa
Organization	KSO Corporation
Division name	Sales department
Address	1-9-7 Shibaura, Minato-ku, Tokyo
TEL	03-3452-7733
Homepage URL
Email	yoshikawa@kso.co.jp

Sponsor
Institute	KSO Corporation
Institute
Department

Funding Source
Organization	Lotte Co., Ltd.
Organization
Division
Category of Funding Organization	Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funｄer(s)

Secondary IDs
Secondary IDs	NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information	2016 Year 05 Month 13 Day

Progress
Recruitment status	Completed
Date of protocol fixation	2016 Year 04 Month 19 Day
Anticipated trial start date	2016 Year 05 Month 15 Day
Last follow-up date	2016 Year 06 Month 16 Day
Date of closure to data entry	2016 Year 08 Month 03 Day
Date trial data considered complete	2016 Year 09 Month 06 Day
Date analysis concluded	2016 Year 11 Month 15 Day

Related information
URL releasing protocol
Publication of results	Published
URL releasing results	http://www.lifescience.co.jp/yk/yk17/mar/ab9.html
Results	Jpn Pharmacol Ther 2017; 45(3): 463-472.
Other related information

Management information
Registered date	2016 Year 05 Month 10 Day
Last modified on	2017 Year 03 Month 30 Day

Link to view the page
URL(English)	https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025630